Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
Ascites are abnormal pockets of fluid that develop in the abdomen. We spoke to gynecologic oncologist Travis Sims, M.D., to learn more about this late-stage…
Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.
If you’re carrying excess weight, those extra pounds can affect many areas of your health, including your risk for cancer. In fact, being overweight or…
Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.
18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.
Physicians’ Education Resource – Newest Continuing Medical Education Live Events, Webcasts & Online Activities
Take this survey powered by surveymonkey.com. Create your own surveys for free.
A recent article pointed out that efforts to decrease low-value care often fall short. It asserted that a primary cause is physicians being financially motivated.